In 252 adults with moderately to severely active ulcerative colitis, oral icotrokinra (an IL-23 receptor-blocking peptide) at 400, 200 or 100 mg daily gave week-12 clinical response in 63%, 58% and 55% vs 27% with placebo (all P<0.001).
RCTn = 252
Abreu et al. Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis